News
CTOR
1.031
+2.04%
0.021
Weekly Report: what happened at CTOR last week (0914-0918)?
Weekly Report · 3d ago
12 Health Care Stocks Moving In Friday's After-Market Session
Benzinga · 5d ago
Weekly Report: what happened at CTOR last week (0907-0911)?
Weekly Report · 09/14 10:19
Weekly Report: what happened at CTOR last week (0831-0904)?
Weekly Report · 09/07 10:13
Weekly Report: what happened at CTOR last week (0824-0828)?
Weekly Report · 08/31 10:20
Weekly Report: what happened at CTOR last week (0817-0821)?
Weekly Report · 08/24 10:20
Citius Oncology GAAP EPS of -$0.08 beats by $0.11, revenue of $1.5M misses by $4.27M
Seeking Alpha · 08/17 12:15
12 Health Care Stocks Moving In Monday's Pre-Market Session
Benzinga · 08/17 12:06
Weekly Report: what happened at CTOR last week (0810-0814)?
Weekly Report · 08/17 10:21
Why HIVE Digital Technologies Shares Are Trading Higher By Over 8%; Here Are 20 Stocks Moving Premarket
Benzinga · 08/17 08:54
Citius Oncology Q3 EPS $(0.08), Inline, Sales $1.494M Miss $2.500M Estimate
Benzinga · 08/14 20:58
*Citius Pharmaceuticals 3Q Rev $1.5M >CTXR
Dow Jones · 08/14 20:34
*Citius Pharmaceuticals 3Q Loss/Shr 34c >CTXR
Dow Jones · 08/14 20:34
*Citius Oncology 3Q Loss/Shr 8c >CTOR
Dow Jones · 08/14 20:31
*Citius Oncology 3Q Rev $1.5M >CTOR
Dow Jones · 08/14 20:31
Press Release: Citius Oncology, Inc. Reports -2-
Dow Jones · 08/14 20:30
Press Release: Citius Pharmaceuticals, Inc. Reports Fiscal Third Quarter 2026 Financial Results and Provides Business Update
Dow Jones · 08/14 20:30
Press Release: Citius Pharmaceuticals, Inc. -2-
Dow Jones · 08/14 20:30
Citius Oncology adds independent director to expanded board
TipRanks · 08/12 12:59
Press Release: Citius Oncology Expands Board with Appointment of Independent Director Jonathan Peri
Dow Jones · 08/12 12:00
More
Webull provides a variety of real-time CTOR stock news. You can receive the latest news about Citius Oncology, Inc. through multiple platforms. This information may help you make smarter investment decisions.
About CTOR
Citius Oncology, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing targeted oncology therapies. The Company’s lead product candidate is LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein, for the treatment of patients with persistent or recurrent CTCL, a rare form of non-Hodgkin lymphoma. LYMPHIR is a targeted immune therapy for relapsed or refractory cutaneous T-cell lymphoma (CTCL) indicated for use in Stage I-III disease after at least one prior systemic therapy. It is a recombinant fusion protein that combines the IL-2 receptor binding domain with diphtheria toxin fragments. The agent specifically binds to IL-2 receptors on the cell surface, causing diphtheria toxin fragments that have entered cells to inhibit protein synthesis. After uptake into the cell, the diphtheria toxin (DT) fragment is cleaved and the free DT fragments inhibit protein synthesis, resulting in cell death.